MT2A and breast carcinoma: None of the 5 tested polymorphisms showed a correlation with cancer risk in studied groups, although some non-significant differences in genotypes frequencies among cases and controls were observed for MMP-2, MMP-7 and MT2A. MMP-2 TT genotype was less frequent among breast cancer patients comparing to controls (4.3% vs 8.4%) (Table 2), but more frequent in lung cancer cases (5% in cases vs 3% in controls) (Table 3).